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A
 
fter the demonstration almost 20 years ago that anti-
bodies to CD2 are potent inhibitors of T cell function,
this cell surface glycoprotein became one of the most in-
tensively studied of all T cell antigens (1–3). The subsequent
identification of LFA-3 (CD58) as a ligand for human CD2
led to the demonstration in cell culture experiments that the
CD2–CD58 interaction dramatically enhanced T cell anti-
gen recognition (1–3). Given this background, it was puz-
zling that no abnormality in T cell function was observed
in the initial experiments on CD2-deficient mice (4, 5). A
subsequent study did detect some alteration in T cell devel-
opment and peripheral T cell responses, but the precise na-
ture of the abnormality was unclear (6). Now work by Bach-
mann and colleagues, described in this issue (7), has clarified
matters by demonstrating that T cells from CD2-deficient
mice have a quantitative defect in antigen recognition: they
 
require a higher concentration of antigen to produce the same
response as wild-type T cells.
CD2 has an extracellular portion with two Ig-like do-
mains, a single membrane-spanning region, and a positively
charged, proline-rich cytoplasmic domain, which is highly
conserved between species (2, 8). It is expressed on T cells
and NK cells in all mammalian species studied to date, but is
also found on B cells in the mouse and splenic macrophages
in the rat and sheep (9). A more significant species difference
is that in the mouse and rat, which do not express CD58, the
major CD2 ligand is CD48 (8). Conversely, human CD2
binds very weakly to CD48. CD2 and its ligands, CD48 and
CD58, are members of a family of structurally related cell
surface molecules termed the CD2 family, which includes
signaling lymphocytic activation molecule (SLAM), CD84,
Ly-9, and 2B4 (8, 10). The observation that these molecules
bind members of the same family suggests that the CD2 fam-
ily evolved from a common ancestral gene that encoded a
homophilic adhesion molecule. Further support for this no-
tion has come from the recent demonstration that 2B4 binds
CD48 (11), and that SLAM self-associates (12). It has also
been reported that human CD2 binds the structurally unre-
lated molecule CD59, but this is controversial (8).
The strategy used by Bachmann et al. to study CD2
function was to cross CD2-deficient mice with transgenic
mice expressing a TCR specific for the lymphocytic chorio-
meningitis virus (LCMV)–derived peptide, p33. In the ab-
sence of CD2, peripheral T cells required 3–10-fold more
p33 peptide to produce the same response in vitro. A similar
quantitative defect was seen when APCs lacking intracellu-
lar adhesion molecule 1 (ICAM-1, a ligand for the T cell
adhesion molecule LFA-1) were used to present antigen.
These differences were more marked when an altered, pre-
sumably low affinity, peptide was used as stimulus. This
suggests that CD2 may lower the affinity as well as the sur-
face density of peptide–MHC required to activate T cells, a
question requiring further study using TCR/peptide–MHC
combinations with known binding properties.
A previous study had shown that CD2-deficient mice
are no more susceptible to LCMV infection than wild-type
mice (5). Bachmann et al. devised a more sensitive assay to
probe for subtle defects. They transferred equal numbers of
CD2-deficient and CD2-sufficient TCR-transgenic T cells
into a mouse and compared the expansion of these two
subsets in response to viral challenge. No difference was de-
tected after infection with live virus competent to replicate
(either LCMV or a recombinant vaccinia virus expressing
the antigenic protein LCMV-GP [vacc-GP]). However, T
cells lacking CD2 expanded poorly when the mice were
challenged with either vacc-GP virus inactivated by UV
light or the viral protein LCMV-GP (administered mixed
together with cellular debris). They reasoned that CD2 only
conferred an advantage to T cells in the latter experiments
because much lower levels of viral antigen would have been
presented than is the case after infection with active virus.
Taken together, these experiments suggest that CD2
quantitatively enhances T cell antigen recognition, thereby
enabling lower concentrations of peptide–MHC to induce
a T cell response. Although the defects observed in CD2-
deficient mice are quite subtle, there are significant differ-
ences in the CD2–ligand system between humans and
mice, suggesting that studies in mice may underestimate
the contribution of CD2 to T cell function in humans.
First, human CD2 binds its major ligand, CD58, with a
5–10-fold greater solution affinity than mouse (or rat) CD2
for CD48 (13). The difference in the more physiologically
relevant “two-dimensional” affinity is even greater (40–50-
fold [14]). This was measured as the surface density of mem-
brane-anchored CD48 or CD58 in planar lipid bilayers re-
quired for half-maximal binding to CD2 on T cells (14). A
second important difference is that, whereas CD58 is very
widely expressed in both hematopoietic and nonhemato-
poietic cells, CD48 expression is largely confined to hemato-
poietic cells and endothelium (9). Finally, in vitro studies
using blocking antibodies (15) or CD2-deficient murine T
cell clones (16) suggest that mouse T cells are less depen-
dent than human T cells on CD2–ligand interactions.
How might the CD2–ligand interaction enhance T cell 
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antigen recognition? One possibility is that the interaction
enhances TCR engagement of peptide–MHC. In support
of this, Bachmann et al. (7) observed that CD2 enhanced
TCR downmodulation, which is thought to correlate with
TCR/peptide–MHC engagement (17), to the same extent
as it enhanced T cell proliferation and cytokine production.
Structural studies have provided important clues to the
mechanism by which CD2 enhances TCR/peptide–MHC
engagement. The solution of the crystal structure of the ex-
tracellular portion of CD2 revealed that CD2 self-associates
in the crystal lattice in a head-to-head orientation, making
contact via its ligand-binding site (8). Given the structural
similarity and evolutionary relationships within the CD2
family, it was proposed that the CD2 would interact with
CD48 and CD58 in the same way (8). Complementary
mutagenesis provided direct evidence that rat CD2 bound
CD48 in a head-to-head orientation (8), and manual dock-
ing of human CD2 onto CD58 strongly supported a head-
to-head orientation for this complex as well (13). The recent
solution of the crystal structure of the CD2–CD58 complex
has provided definitive proof that human CD2 binds CD58
in the same orientation (18). Since such a CD2–ligand com-
plex would span the same distance as the TCR/peptide–
MHC complex (
 
z
 
14 nm), it was suggested that CD2–ligand
interactions might function to position the membranes of the
T cell and APC at a separation distance optimal for TCR
engagement of peptide–MHC, forming what have been
termed “close contact zones” (8). In support of this is the
demonstration that the dimensions of the CD2–CD48 com-
plex have a critical influence on T cell antigen recognition
(19): whereas the wild-type CD2–CD48 interaction en-
hances T cell antigen recognition, an elongated CD2–CD48
(
 
.
 
21 nm) interaction is strongly inhibitory.
Low-resolution structural data suggest that the LFA-1/
ICAM-1 interaction would span a much greater distance
(30–50 nm) than the CD2–ligand interaction (9), implying
that the LFA-1/ICAM-1 interaction must enhance TCR/
peptide–MHC engagement by a distinct mechanism. This
is supported by the finding that the effects of CD2 and
ICAM-1 are approximately additive (7). How then does the
LFA-1/ICAM-1 interaction enhance TCR engagement of
peptide–MHC? One possibility is that it helps form initial
T cell–APC contacts. Dustin and colleagues observed that,
after the formation of LFA-1/ICAM-1 adhesion contacts
between T cells and planar lipid bilayers presenting pep-
tide–MHC, more intimate close contacts formed surround-
ing the LFA-1/ICAM-1 contacts, despite the absence of
any other adhesion molecules in the bilayers (20). They
propose that T cells use LFA-1/ICAM-1 adhesion contacts
as a fulcrum for “cytoskeletal protrusive mechanisms” that
force the membranes into close proximity, thereby helping
to form close contact zones.
A glaring omission from the model of CD2 function
proposed above is any role for the cytoplasmic domain.
This is very highly conserved between species, indicating
that it must contribute in an important way to CD2 func-
tion. Indeed, truncation of the cytoplasmic domain decreased
(although it did not abolish) the enhancing effect of CD2
on T cell antigen recognition (21, 22). Two distinct roles
have been proposed for the cytoplasmic domain, transduc-
tion of a signal and the regulation of adhesion.
The notion that the CD2 cytoplasmic domain has a sig-
naling role originates from observations many years ago that
certain combinations of antibodies to human or rat CD2 can
trigger T cell activation, and that these effects require an
intact cytoplasmic domain (2, 23). Numerous subsequent
studies have used antibody-induced T cell activation to de-
lineate putative signaling pathways. However, given that
there is no direct evidence that a physiological interaction
between CD2 on T cells with a ligand on targets cells or
APCs transduces a signal to T cells, it remains possible that
antibody-induced signaling is an artefact with little physio-
logical relevance. The effects of anti-CD2 antibodies may
simply be a consequence of the cross-linking of CD2-asso-
ciated molecules such as the TCR–CD3 complex. The ob-
servation that CD2 enhances, but is not essential for, T cell
function makes it unlikely that CD2 transduces a unique
and functionally important signal, independent of the TCR–
CD3 complex. It seems more likely that CD2 modulates
TCR triggering by recruiting signaling molecules into the
vicinity of the TCR–CD3 complex. Several such mole-
cules have been implicated through their ability to bind di-
rectly to proline-rich motifs in the CD2 cytoplasmic do-
main, including the tyrosine kinase lck (24), the adaptor
molecule CD2BP1 (25) (which binds to a tyrosine phos-
phatase), and CD2BP2 (26). The precise contributions of
these molecules to CD2 function remain to be determined.
A second proposed role for the CD2 cytoplasmic do-
main is modulation of the adhesion function of CD2. The
first evidence for such a role was the observation that acti-
vation of T cells enhanced their adhesion to surfaces coated
with purified CD58, and that the cytoplasmic domain of
CD2 was required for the effect (27). It was subsequently
shown that the cytoplasmic domain of CD2 influences its
distribution within adhesion contacts between T cells and
planar lipid bilayers (28). Molecules segregate into distinct
clusters (supramolecular activation clusters [SMACs]) at the
interface between T cells and target cells or APCs, forming
an organized interface termed the immunological synapse
(20, 29; for a review, see reference 30). There is a central
cluster (cSMAC) containing the TCR, CD28, and several
signaling molecules, and a peripheral cluster (pSMAC) or
outer adhesion ring containing LFA-1 and ICAM-1. Dus-
tin and colleagues observed that CD2 segregates into a dis-
tinct “inner” adhesion ring surrounding the cSMAC but
within the pSMAC (20). Given the similarity in size be-
tween CD2–ligand and TCR/peptide–MHC complexes,
this finding was unexpected, and it raises several questions.
What mechanisms drive the segregation of CD2 into this
inner adhesion ring? It seems likely that cytoskeletally
driven transport processes are responsible, and, given its
role in influencing the distribution of CD2 in contact sites
(28), the recently identified CD2-associated protein (CD2AP)
is a plausible link between CD2 and the cytoskeleton. The
availability of CD2AP-deficient mice (31) should enable
this hypothesis to be tested in the near future. Interestingly, 
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these mice have a more severe defect in T cell activation
than CD2-deficient mice, suggesting that CD2AP has a
broader role than CD2 in T cell function.
What is the function of the inner adhesion ring? Dustin
and colleagues (20) have proposed that it may function as a
molecular size “filter,” preventing molecules larger than
 
z
 
15 nm from being transported into the cSMAC. In this
context, it is interesting that CD2AP, which is widely ex-
pressed, is reported to associate with nephrin (31) and p130
 
Cas
 
(32), proteins that are associated with specialized cell–cell
junctions in other tissues. Furthermore, ectopic expression
of CD2AP results in cytoskeletal changes (32). These data
are consistent with the notion that CD2AP contributes to
the formation of specialized cell–cell junctions such as the
inner adhesion ring by coupling cell surface molecules to
the cytoskeleton.
The “filtration model” for CD2 function does not ex-
plain why elongation of CD2–CD48 inhibits T cell antigen
recognition to levels below that seen in the complete ab-
sence of CD2–CD48 (19). However, these data can be rec-
onciled if it is proposed that CD2 has two distinct functions
during T cell antigen recognition. Current evidence sug-
gests that immunological synapse formation involves the
active redistribution of cell surface molecules, and that this
redistribution follows and is dependent on initial TCR
triggering (20, 30). The first function of CD2–ligand may
be to enhance this initial TCR triggering by positioning
the membranes the optimal distance apart (8). After TCR
triggering, CD2 is actively redistributed to the inner adhe-
sion ring (20) where it may have a second function as a
molecular filter, thereby helping to maintain the structure
of the immunological synapse (20). It is likely that the ini-
tial, membrane-approximation function can be fulfilled by
any interaction, such as the CD28–ligand interaction, that
has the same dimensions as the CD2–ligand complex.
The fact that CD2 has been conserved throughout mam-
malian evolution suggests that the quantitative effect that
CD2 has on T cell antigen recognition must provide a sig-
nificant survival advantage. What is this survival advantage?
Perhaps the ability to recognize lower concentrations of
peptide–MHC enables responses to be mounted earlier af-
ter infection and/or facilitates the elimination of residual
infectious agent. Another possibility is that the CD2–ligand
interaction alters the repertoire of T cells that are selected
in the thymus. It has been pointed out that, because T cell
clones carrying TCRs with a low affinity for peptide–
MHC will be more common than those with a high affin-
ity, an ability to respond to lower affinity peptide–MHC
complexes would increase the effective size of the T cell
repertoire, thereby increasing the likelihood that any par-
ticular T cell will respond to any particular antigen (8).
Testing this hypothesis will require a technique for measur-
ing small changes in the size of the T cell repertoire.
In conclusion, the CD2–ligand interaction enables T
cells to respond to lower concentrations of antigens. One
mechanism for this enhancement is the bringing together
of T cell and APC or target cell plasma membranes to a
separation distance that is optimal for TCR engagement of
peptide–MHC. It seems likely that other lymphocyte mol-
ecules will also have quantitative effects on immune func-
tion. The lesson from CD2 is that sensitive experiments
will be needed to detect these subtle effects.
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